Skip to main content


BPL sells 25 US plasma centres to Grifols for $370 million (£265 million)

01 March 2021

Bio Products Laboratory (BPL) announces today the completion of a US$370 million (£265 million) transaction for the sale of 25 of its 51 US-based plasma centres to Biomat USA Inc, a subsidiary of Grifols S.A., a global healthcare company. Approximately 730 employees will be transferring to Biomat as part of the deal.

Read full article

Government decision to remove ban on UK-sourced plasma

26 February 2021

BPL welcomes the decision made by Government to lift the ban on UK plasma being used for the manufacture of immunoglobulins. BPL is very supportive of this Government initiative which will result in plasma from UK blood donors being used to manufacture life-saving medicines, and will help the UK become self-sufficient in plasma supply.

Read full article

Bio Products Laboratory Announces Launch of ALBUMINEX® 5% and ALBUMINEX® 25% With Supply Immediately Available in the United States

27 May 2020

Bio Products Laboratory (BPL), a leading manufacturer of plasma-derived protein therapies with US headquarters in Durham, North Carolina, and worldwide headquarters and manufacturing facilities in Elstree, UK, today announced the US launch of ALBUMINEX 5% (human albumin) solution for injection and ALBUMINEX 25% (human albumin) solution for injection, with supply immediately available.

Read full article